Enamine - smart chemistry solutions
NEWS AND EVENTS
Press Releases


Press Releases
Enamine to Collaborate with EMBL for Cancer Drug Discovery Research
April 25, 2017

Enamine Ltd. and the European Molecular Biology Laboratory (EMBL) have agreed to establish a collaboration whereby Enamine provides library synthesis, medicinal chemistry and biological services for the discovery and development of novel small molecules against EMBL’s proprietary anti-cancer targets.
Read press release

 

Enamine expands collaboration with Actelion Pharmaceuticals
January 23, 2017

Enamine Ltd. has announced that it has agreed to expand its collaboration in early drug discovery with Actelion Pharmaceuticals, covering therapeutic areas including cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.
Read press release

 

Enamine and Pcovery extend drug discovery collaboration
November 22, 2016

Enamine Ltd. and Danish biotech company Pcovery have announced that they have extended their collaboration for the discovery of new drugs for the treatment of invasive fungal infections and platform technology development.
Read press release

 

Enamine and FCH Group collaborate to extend compound library synthesis program
October 24, 2016

Enamine Ltd., a chemical company, producer of building blocks and screening libraries, announced today that it had signed a collaboration agreement with small molecule design house FCH Group Ltd (FCH).
Read press release

 

Chem-Space Launches to Provide Largest Global Chemical Database and Search Tool
March 01, 2016

Enamine, ChemBridge Corporation, UORSY and FCH Group today announced launch of Chem-Space, a global e-procurement marketplace solution for searching, purchasing and selling chemical building blocks. The Chem-Space database currently encompasses over 15 million unique molecular building blocks, and is the world’s largest chemicals library.
Read press release

 

Enamine is expanding its purification and analytical units to enhance library synthesis offering
November 12, 2015

Enamine is announcing today the expansion of its Purification and Analytical Units to enable synthesis of 30 000 high quality screening library compounds monthly. Such expansion represents the largest development to date of its library synthesis capabilities.
Read press release

 

Enamine Announces Extension of Collaboration with Sanofi in Early Drug Discovery
December 18, 2014

Following the success since 2012 the collaboration with Sanofi aiming at finding of new valuable hit series in most challenging screening campaigns has been extended.
Read press release

 

Drug Discovery collaboration with BioVersys AG extended
December 02, 2014

Collaboration with BioVersys AG aiming at discovery of novel treatments against bacterial infections has been extended for the 4th consecutive year.
Read press release

 

Axxam acquires a 240 000 carefully selected compounds library from Enamine for drug discovery programs
September 23, 2013

Axxam S.p.A., a contract research and discovery company, announced today that an entirely new generation screening collection is now available for drug discovery programs: AXXDIV2.0 made up with 240 000 carefully selected small molecules.
Read press release

 

Enamine Provides Exquiron with Large Novel Diverse Screening Compound Library
June 03, 2013

Enamine and Exquiron are announcing a multi-year collaboration wherby Exquiron is acquiring a large screening compounds libraries from Enamine.
Read press release

 

ChanTest announces drug discovery services using the Enamine 3D compound library
October 15, 2012

3D Diversity Set from Enamine, containg 50 000 drug-like compounds, has been selected by ChanTest for their dicovery services using powerful HTS of Ion Channels, GPCRs and Transporters in partnership with pharma and biotech companies.
Read press release

 

Enamine creates the alliance to discover novel Rhomboid Protease inhibitors as potential drugs
June 06, 2012

A collaboration agreement has been signed between Enamine, the Medical Research Council Laboratory of Molecular Biology (MRC LMB), Cambridge, UK, and the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (IOCB), Prague, Czech Republic. The new alliance is aimed at discovering novel Rhomboid Protease inhibitors as potential drugs to treat infectious, parasitic, oncological, immune and cardiovascular diseases. Enamine will provide the MRC LMB and IOCB with access to its integrated drug discovery capabilities, including Molecular Modeling, Compound Library, Screening Assays, Hit Finding and Characterization, Hit to Lead Chemistry and ADMET. The three parties will seek to partner the small molecule inhibitors generated with pharmaceutical companies for onward clinical development. The collaboration agreement was negotiated by MRC Technology on behalf of MRC LMB.
Read press release

 

Collaboration agreement has been signed with UORSY
April 18, 2012

Enamine and UkrOrgSynthesis Ltd (UORSY), a leading Ukrainian supplier of chemical building blocks and compounds for high-throughput screening, announced they have signed a collaboration agreement to offer chemical building blocks to the drug discovery industry cooperatively. By combining their catalogues, the companies become the largest global manufacturer and seller of building blocks, with 60 000 products available from stock for immediate delivery and an array of ca. 8 million tangible building blocks deliverable with synthetic success rate of 80%.
Read press release

 

Enamine Provides Large Novel Diverse Compound Screening Library To Extend Relationship with BioFocus
January 31, 2012

Enamine Ltd, a leading provider of screening compounds and chemical building blocks, today announced it has extended its long-standing relationship with BioFocus, with the acquisition by BioFocus of a large new compound screening library. The library will be available to BioFocus HTS collaborators in early 2012.
Read press release

 

Molplex and Enamine announced a new partnership
January 24, 2010

Molplex and Enamine announced a new partnership to offer Enamine's screening compounds through the Molplex on-line drug design and assay ready chemical supply services. The agreement is a major step towards eliminating the high start-up costs of drug discovery, bringing sophisticated drug design, compound management and assay ready chemistry to the world's drug discovery scientists on demand. The agreement adds Molplex online drug design systems to the deep experience in organic chemistry and compound management of Enamine to solve the problem of generating viable chemical leads for novel targets.
Read press release

 



© 1991 - 2017 ENAMINE